GSTM1 and cold agglutinin disease: As illustrated in Figure 3, among 10 evaluable CAD patients, 5 met the primary endpoint of a Hb level increase of ≥ 1.5 g/dL above baseline sustained for at least two consecutive weeks without the use of rescue therapy.